« BACK

Pharmacology



Results 1 - 19 of 19.


Health - Pharmacology - 08.02.2019
Drug-resistant tuberculosis: high mortality rate due to inaccurate tests
Drug-resistant tuberculosis: high mortality rate due to inaccurate tests
Inaccurate tests carried out on tuberculosis patients in developing countries often fail to reliably detect resistance to drugs, leading to incorrect treatment and a higher mortality rate. These are the results of study by an international group of researchers led by a team at the University of Bern published today.

Health - Pharmacology - 05.02.2019
Even psychological placebos have an effect
Even psychological placebos have an effect
Placebo effects do not only occur in medical treatment - placebos can also work when psychological effects are attributed to them. Psychologists from the University of Basel reported these findings in the journal Scientific Reports, based on three studies with over 400 participants. Psychotherapy and placebos are both psychological interventions that not only have comparable effects, but that are also based on very similar mechanisms.

Chemistry - Pharmacology - 01.02.2019
Intuition and failure are valuable ingredients in chemistry
Intuition and failure are valuable ingredients in chemistry
When researchers make a new discovery, they tend to only publish the results of their successful experiments. But just as informative are all the experiments that didn't work - the failed trials and incorrect hypotheses, which can offer important information. A team of EPFL chemists has developed a methodology for collecting those lessons and, crucially, sharing them with other researchers.

Health - Pharmacology - 14.01.2019
Conversion of breast cancer cells into fat cells impedes the formation of metastases
Conversion of breast cancer cells into fat cells impedes the formation of metastases
An innovative combination therapy can force malignant breast cancer cells to turn into fat cells. This can be used to prevent the formation of metastases in mice, as researchers at the University of Basel's Department of Biomedicine recently reported in the journal Cancer Cell. Tumor cells can adapt dynamically to changing conditions thanks to their ability to reactivate a cellular process that is central to embryonic development.

Health - Pharmacology - 10.01.2019
New drug against the formation of metastasis
New drug against the formation of metastasis
The most deadly aspect of breast cancer is metastasis. It spreads cancer cells throughout the body. Researchers at the University and the University Hospital of Basel have now discovered a substance that suppresses the formation of metastases. The development of metastasis is responsible for more than 90% of cancer-related deaths, and patients with a metastatic disease are considered incurable.

Pharmacology - Life Sciences - 10.01.2019
How Drugs Can Minimize the Side Effects of Chemotherapy
Researchers at the University of Zurich have determined the three-dimensional structure of the receptor that causes nausea and vomiting as a result of cancer chemotherapy. The study explains for the first time why some drugs work particularly well in ameliorating these side effects. The results also provide important insights into how to develop compounds to effectively tackle other disorders.

Health - Pharmacology - 02.01.2019
Tumors backfire on chemotherapy
Chemotherapy is an effective treatment for breast cancer, yet some patients develop metastasis in spite of it. Researchers at EPFL have discovered that chemotherapy-treated mammary tumors produce small vesicles that may help them spread to other organs. The study is published. Some patients with breast cancer receive chemotherapy before the tumor is removed with surgery.

Pharmacology - Health - 18.12.2018
Buruli Ulcer: Promising New Drug Candidate Against a Forgotten Disease
Buruli Ulcer: Promising New Drug Candidate Against a Forgotten Disease
Buruli ulcer is a neglected tropical disease (NTD) resulting in debilitating skin lesions, disabilities and stigmatisation. The current antibiotic treatment is long and has severe adverse side effects. Researchers from the Swiss Tropical and Public Health Institute (Swiss TPH) together with colleagues from Singapore have discovered a highly effective compound against Buruli ulcer which has the potential to become a powerful alternative to the existing treatment options.

Pharmacology - Health - 18.12.2018
Buruli ulcer: New drug against a forgotten disease
Buruli ulcer: New drug against a forgotten disease
Buruli ulcer is a neglected tropical disease (NTD) resulting in debilitating skin lesions and disabilities. The current antibiotic treatment is long and has severe adverse side effects. Researchers from the Swiss Tropical and Public Health Institute (Swiss TPH), which is associated with the University of Basel, together with colleagues from Singapore have discovered a highly effective compound against Buruli ulcer.

Health - Pharmacology - 14.12.2018
Modelling for New Schistosomiasis Treatment Thresholds
Modelling for New Schistosomiasis Treatment Thresholds
Schistosomiasis is a parasitic worm infection affecting 250 million people globally. The current prevalence thresholds for preventive chemotherapy of schistosomiasis are based on the Kato-Katz method using stool samples. A new more sensitive point-of-care urine test is now available in particular for settings with low prevalence.

Pharmacology - Health - 11.12.2018
Lethal combination: Drug cocktail turns off the juice to cancer cells
Lethal combination: Drug cocktail turns off the juice to cancer cells
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth - this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, recently published in "Cell Reports", the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

Health - Pharmacology - 06.12.2018
Statins Overprescribed for Primary Prevention
Taking cholesterol-lowering drugs, or statins, as a preventive measure can reduce the risk of cardiovascular disease. A study by the University of Zurich now shows that this measure is recommended too often, as current guidelines fail to take into account the risks of side effects. Even healthy people who don't suffer from a cardiovascular disease are prescribed cholesterol-lowering drugs, known as statins, if they meet certain risk criteria.

Health - Pharmacology - 28.11.2018
New Stem-Cell Therapy to Improve Fight against Leukemia
Stem-cell transplantation is an effective form of therapy to fight leukemia. In many cases, however, the transferred immune cells of the donor also attack the recipients' healthy tissue ' often with fatal consequences. Researchers at the University of Zurich have now identified a molecule that plays a key role in this process.

Pharmacology - Health - 19.11.2018
From Receptor Structure to New Osteoporosis Drugs
From Receptor Structure to New Osteoporosis Drugs
Researchers have determined the three-dimensional structure of a receptor that controls the release of calcium from bones. The receptor is now one of the main candidates for developing new drugs to treat osteoporosis. Knowing the receptor's blueprint will be instrumental for designing drugs that could even help to rebuild bones.

Health - Pharmacology - 22.10.2018
Roche’s Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer
Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer Head-to-head phase III study of Alecensa versus crizotinib in Asian patient population showed a reduction in the risk of disease worsening or death by 78% Alecensa lowered the risk of tumour spread or growth in the brain or central nervous system

Health - Pharmacology - 02.10.2018
Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS
Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS Data reinforce importance of early initiation and continuation of OCREVUS treatment New analyses highlight the need for active treatment in underrepresented populations, such as primary progressive MS (PPMS) patients with more advanced disability and relapsing MS (RMS) patients of African descent Roche

Pharmacology - Health - 30.08.2018
Positive phase III results for Roche’s Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine
Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis Hemlibra is the first medicine to demonstrate superior efficacy to prior factor VIII prophylaxis based on a statistically significant reduction in treated bleeds in an intra-patient comparison Hemlibra is currently under Priority Review by the FDA for people with haemophilia A without factor VIII inhibitors Roche today announced that pivotal data from the phase III HAVE

Pharmacology - Health - 15.06.2018
New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
After a follow-up time of nearly five years the CLL11 study shows a 51% reduction in the risk of disease progression or death with Gazyva/Gazyvaro compared to MabThera/Rituxan The final analysis reports a clinically meaningful overall survival benefit is seen for Gazyva/Gazyvaro compared to MabThera/Rituxan when combined with chlorambucil These data highlight the superiority of Gazyva/Gazyvaro-based treatment over MabThera/Rituxan-based treatmen

Life Sciences - Pharmacology - 16.04.2018
Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline
Breadth of data will reinforce efficacy and safety of OCREVUS in relapsing and primary progressive multiple sclerosis and demonstrate its benefits in slowing disability progression, including new cognitive and biomarker results Important research in Alzheimer's disease, Huntington's disease, Spinal Muscular Atrophy and Duchenne Muscular Dystrophy will highlight the strength of Roche's neuroscience pipeline Roche announced today that new data on